{
  "name": "Standardized Cardiac Ion Channel Block Potencies, Safety Margins, and Perfusion Adsorption Loss for Reference Drugs",
  "description": "Compiled multi-laboratory benchmark dataset comparing in vitro hERG (IKr), late Nav1.5, and Cav1.2 inhibitory concentrations (IC50) with clinical free Cmax, Redfern safety margins, lipophilicity (LogP), and perfusion apparatus drug loss across eight reference pharmaceuticals evaluated under ICH S7B Q&A 2.1 and CiPA electrophysiology protocols.",
  "page": "https://casrai.org/guides/herg-assay",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-15T10:46:05Z",
  "temporalCoverage": "2003/2025",
  "spatialCoverage": "International",
  "columns": [
    {
      "name": "Compound",
      "unit": "",
      "description": "Pharmaceutical reference substance evaluated in cardiac safety pharmacology benchmarking"
    },
    {
      "name": "Clinical TdP Risk Category",
      "unit": "",
      "description": "Torsadogenic risk classification established by clinical registries and Redfern et al."
    },
    {
      "name": "Manual Patch Clamp hERG IC50",
      "unit": "nM",
      "description": "Concentration producing 50% inhibition of peak hERG tail current at near-physiological temperature"
    },
    {
      "name": "Free Therapeutic Cmax",
      "unit": "nM",
      "description": "Maximum unbound therapeutic human clinical plasma concentration"
    },
    {
      "name": "Safety Margin (hERG IC50 / Free Cmax)",
      "unit": "ratio",
      "description": "Ratio of in vitro hERG IC50 to unbound clinical Cmax; Redfern safety threshold benchmark is 30"
    },
    {
      "name": "Late Nav1.5 IC50",
      "unit": "µM",
      "description": "Inhibitory concentration for cardiac late sodium current evaluated in recombinant expression systems"
    },
    {
      "name": "Cav1.2 IC50",
      "unit": "µM",
      "description": "Inhibitory concentration for cardiac L-type calcium current evaluated in recombinant expression systems"
    },
    {
      "name": "LogP",
      "unit": "LogP",
      "description": "Octanol-water partition coefficient reflecting molecular lipophilicity"
    },
    {
      "name": "Perfusion Apparatus Drug Loss",
      "unit": "%",
      "description": "Average percentage compound mass loss in perfusion tubing and chambers due to non-specific binding"
    }
  ],
  "rows": [
    {
      "Compound": "Dofetilide",
      "Clinical TdP Risk Category": "High",
      "Manual Patch Clamp hERG IC50": 12,
      "Free Therapeutic Cmax": 2,
      "Safety Margin (hERG IC50 / Free Cmax)": 6,
      "Late Nav1.5 IC50": 100,
      "Cav1.2 IC50": 100,
      "LogP": 1.3,
      "Perfusion Apparatus Drug Loss": 8.5
    },
    {
      "Compound": "Cisapride",
      "Clinical TdP Risk Category": "Intermediate",
      "Manual Patch Clamp hERG IC50": 10.1,
      "Free Therapeutic Cmax": 4,
      "Safety Margin (hERG IC50 / Free Cmax)": 2.5,
      "Late Nav1.5 IC50": 32,
      "Cav1.2 IC50": 25,
      "LogP": 3.4,
      "Perfusion Apparatus Drug Loss": 54
    },
    {
      "Compound": "Terfenadine",
      "Clinical TdP Risk Category": "Intermediate",
      "Manual Patch Clamp hERG IC50": 56,
      "Free Therapeutic Cmax": 4,
      "Safety Margin (hERG IC50 / Free Cmax)": 14,
      "Late Nav1.5 IC50": 1.3,
      "Cav1.2 IC50": 0.9,
      "LogP": 4.8,
      "Perfusion Apparatus Drug Loss": 78
    },
    {
      "Compound": "Verapamil",
      "Clinical TdP Risk Category": "Low",
      "Manual Patch Clamp hERG IC50": 143,
      "Free Therapeutic Cmax": 81,
      "Safety Margin (hERG IC50 / Free Cmax)": 1.8,
      "Late Nav1.5 IC50": 15,
      "Cav1.2 IC50": 0.2,
      "LogP": 3.8,
      "Perfusion Apparatus Drug Loss": 42
    },
    {
      "Compound": "Ranolazine",
      "Clinical TdP Risk Category": "Low",
      "Manual Patch Clamp hERG IC50": 11500,
      "Free Therapeutic Cmax": 1940,
      "Safety Margin (hERG IC50 / Free Cmax)": 5.9,
      "Late Nav1.5 IC50": 5.9,
      "Cav1.2 IC50": 50,
      "LogP": 1.8,
      "Perfusion Apparatus Drug Loss": 12
    },
    {
      "Compound": "Sotalol",
      "Clinical TdP Risk Category": "High",
      "Manual Patch Clamp hERG IC50": 124000,
      "Free Therapeutic Cmax": 14700,
      "Safety Margin (hERG IC50 / Free Cmax)": 8.4,
      "Late Nav1.5 IC50": 300,
      "Cav1.2 IC50": 300,
      "LogP": -0.8,
      "Perfusion Apparatus Drug Loss": 3
    },
    {
      "Compound": "Quinidine",
      "Clinical TdP Risk Category": "High",
      "Manual Patch Clamp hERG IC50": 550,
      "Free Therapeutic Cmax": 870,
      "Safety Margin (hERG IC50 / Free Cmax)": 0.63,
      "Late Nav1.5 IC50": 16,
      "Cav1.2 IC50": 14,
      "LogP": 2.9,
      "Perfusion Apparatus Drug Loss": 28
    },
    {
      "Compound": "Diltiazem",
      "Clinical TdP Risk Category": "Low",
      "Manual Patch Clamp hERG IC50": 17300,
      "Free Therapeutic Cmax": 125,
      "Safety Margin (hERG IC50 / Free Cmax)": 138.4,
      "Late Nav1.5 IC50": 100,
      "Cav1.2 IC50": 0.45,
      "LogP": 2.8,
      "Perfusion Apparatus Drug Loss": 22
    }
  ],
  "sources": [
    {
      "title": "Alvarez Baron et al. (2025) Multi-laboratory comparisons of manual patch clamp hERG data",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357877/",
      "accessed": "2026-11-15"
    },
    {
      "title": "Alvarez Baron et al. (2022) hERG block potencies for 5 positive control drugs",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35792285/",
      "accessed": "2026-11-15"
    },
    {
      "title": "Crumb et al. (2016) An evaluation of 30 clinical drugs against the CiPA ion channel panel",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27060526/",
      "accessed": "2026-11-15"
    },
    {
      "title": "Redfern et al. (2003) Relationships between preclinical cardiac electrophysiology and torsade de pointes",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12667944/",
      "accessed": "2026-11-15"
    }
  ]
}